Live Breaking News & Updates on Plus exemestane

Stay updated with breaking news from Plus exemestane. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of. ....

Japan , Cambridge , Cambridgeshire , United-kingdom , Canada , Jerusalem , Israel-general , Israel , Daiichi-sankyo , Trastuzumab-deruxtecan , Capecitabine-monotherapy , End-results-program